We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Mark
Gilchrist
m.gilchrist@exeter.ac.uk
Jennifer
Williams
jennifer.williams12@nhs.net
Jennifer
Williams
jennifer.williams12@nhs.net
Renal failure
This information is provided directly by researchers and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information.
For people with kidney failure the work of the kidneys is done by dialysis. Peritoneal dialysis is one form of dialysis that patients can do every day in their own home. A plastic tube placed surgically in the abdominal wall allows dialysis fluid to be drained into the abdominal cavity. Toxins that would normally be removed by the kidneys and excess fluid the body doesn’t need pass through a natural membrane in the abdomen into the dialysis fluid. The dialysis fluid is then drained out and discarded.
People on dialysis are at much higher risk of developing heart disease than the general population. One factor which may contribute to this is the large amount of sugar that is used in the peritoneal dialysis fluid. The sugar is required in the dialysis fluid to stimulate the movement of toxins out of the body. But some of the sugar in the fluid passes from the abdomen into the body. We know that uncontrolled sugar levels in the blood can lead to diabetes, heart attacks and strokes.
We will be asking patients who don’t have diabetes to wear a small glucose sensor on their arm for 72 hours. Half of these patients will be on peritoneal dialysis and the other half will be patients with declining kidney function who are not yet on dialysis This will allow us to measure what effect the process of peritoneal dialysis has on blood sugar levels.
We hope that a greater understanding of this process will help us to develop treatments which may be able to protect against some of these damaging effects. And ultimately improve patients’ quality of life.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Case-controlled study;
You can take part if:
You may not be able to take part if:
For the dialysis group Established diagnosis of diabetes mellitus Peritonitis, exit site infection or tunnel infection treated with antibiotics within the last 30 days Use of variable dose of medications known to influence glucose metabolism e.g. glucocorticoids Chronic or active pancreatitis Having a serious disease or condition considered by the investigators to interfere with the results of the study For the control group Established diagnosis of diabetes mellitus Use of variable dose of medications known to influence glucose metabolism e.g. glucocorticoids Chronic or active pancreatitis Having a serious disease or condition considered by the investigators in interfere with the results of the study
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Jennifer
Williams
jennifer.williams12@nhs.net
Dr
Mark
Gilchrist
m.gilchrist@exeter.ac.uk
Jennifer
Williams
jennifer.williams12@nhs.net
The study is sponsored by University of Exeter and funded by Kidney Research UK (KRUK); BLOODWISE (Blood Cancer UK); .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 34912
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
